top of page

Study shows Victoza reduces the risk of major adverse cardiovascular events

Novo Nordisk has announced top-line results from the LEADER trial investigating the cardiovascular safety of Victoza (liraglutide) over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page